Results 41 to 50 of about 18,120 (266)

High Precision Use of Botulinum Toxin Type A (BONT-A) in Aesthetics Based on Muscle Atrophy, Is Muscular Architecture Reprogramming a Possibility? A Systematic Review of Literature on Muscle Atrophy after BoNT-A Injections

Toxins, 2022
Improvements in Botulinum toxin type-A (BoNT-A) aesthetic treatments have been jeopardized by the simplistic statement: “BoNT-A treats wrinkles”. BoNT-A monotherapy relating to wrinkles is, at least, questionable.
Alexander D. Nassif, Ricardo F. Boggio, Sheila Espicalsky, Gladstone E. L. Faria   +3 more
doaj   +1 more source

Designed Azolopyridinium Salts Block Protective Antigen Pores In Vitro and Protect Cells from Anthrax Toxin [PDF]

, 2013
Background:Several intracellular acting bacterial protein toxins of the AB-type, which are known to enter cells by endocytosis, are shown to produce channels.
A Kronhardt, A Messmer, A Ménard, A Ménard, AA Verveen, AF Kintzer, AM Friedlander, Anika Bronnhuber, AW Artenstein, BA Krantz, C Andersen, C Bachmeyer, C Bachmeyer, C Petosa, Christoph Beitzinger, CT Bahner, D Blöcker, D Blöcker, DB Lacy, EM Nestorovich, EM Nestorovich, F Conti, F Orlik, F Orlik, F Tonello, F Tonello, F Wohnsland, G Hajós, G Timári, G Vitale, György Hajós, H Barth, H Barth, Holger Barth, I Zornetta, J Sun, J Wesche, JA Young, JC Milne, JL Elliott, K Cunningham, KA Bradley, Kerstin Duscha, L Abrami, L Abrami, L Abrami, L Abrami, L Song, Ludger Johannes, M Eigen, M Mock, Markus Huber-Lang, MJ Brown, NS Duesbery, PC Hanna, R Benz, R Benz, R Palkó, R Pellizzari, RJ Collier, RO Blaustein, RO Blaustein, Roland Benz, S Nekolla, SH Leppla, SM Bezrukov, SM Bezrukov, T Neumeyer, T Neumeyer, T Neumeyer, TC Dixon, V Escuyer, VA Karginov, VA Karginov, VA Karginov, Y Singh, Zsuzsanna Riedl   +76 more
core   +7 more sources

Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use. A systematic review [PDF]

, 2017
A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic use of abobotulinumtoxinA was conducted.
Cohen, Joel L, Scuderi, Nicolo'
core   +1 more source

Dosage of botulinum toxin in patients undergoing treatment for hemifacial spasm: is there modification during follow-up?

Arquivos de Neuro-Psiquiatria
Background The movement disorder known as hemifacial spasm is characterized by involuntary contractions of the muscles that are innervated by the facial nerve. The treatment of choice for this condition is botulinum toxin injections.
Fátima de Menezes Dantas, Felipe Olobardi Freire, Agábio Diógenes Pessoa Neto, Clécio de Oliveira Godeiro Júnior, Rodrigo Alencar e Silva   +4 more
doaj   +1 more source

Botulinum Toxin Type a in Cervical Dystonia

International Journal of Immunopathology and Pharmacology, 2012
Cervical dystonia is a syndrome characterized by anomalous postures and unintentional repetitive movements of the head and the neck. Aim of this study is to show the effectiveness of the combined treatment botulinum toxin-FKT through the use of a recent methodic of investigation, myoton, and of the classical clinical evaluations, such as Tsui and VAS ...
Marvulli R., Ianieri G., Megna G., Lancioni G., SAGGINI, Raoul, Ranieri M., Cristella G., Megna M.   +7 more
openaire   +3 more sources

Uses of Botulinum Toxin in Headache and Facial Pain Disorders: An Update

Toxins
Botulinum toxin is a neurotoxin that is used in the treatments for several medical conditions, such as dystonia, spasticity, hemifacial spasm, overactive bladder, and hyperhidrosis.
Pedro Augusto Sampaio Rocha-Filho, Moises Dominguez, Christopher L. Robinson, Sait Ashina   +3 more
doaj   +1 more source

Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins. [PDF]

, 2020
Botulinum neurotoxin (BoNT) is one of the most acutely lethal toxins known to humans, and effective treatment for BoNT intoxication is urgently needed. Single-domain antibodies (VHH) have been examined as a countermeasure for BoNT because of their high ...
Jin, Rongsheng, Lam, Kwok-Ho, McNutt, Patrick M, Ondeck, Celinia, Perry, Kay, Shoemaker, Charles B, Tremblay, Jacqueline M, Vazquez-Cintron, Edwin, Webb, Robert P   +8 more
core  

Genetically Confirmed Schwartz–Jampel Syndrome: An Ultra-Rare Case of Congenital Myotonia with Osteochondrodysplasia from India

International Journal of Medical Students
Background: Schwartz–Jampel syndrome is a rare autosomal recessive disorder caused by mutations in the HSPG2 gene, leading to perlecan deficiency. Perlecan is a heparan sulfate proteoglycan critical for cartilage integrity, basement membrane stability ...
Nandita Jali, Suvarna Magar, Tanya Trikha, Varsha Vaidya, Viranchi Vaidya   +4 more
doaj   +1 more source

Clinical Recovery and Circulating Botulinum Toxin Type F in Adult Patient

Emerging Infectious Diseases, 2009
A 56-year-old woman in Helena, Montana, USA, who showed clinical signs of paralysis, received antitoxins to botulinum toxins A, B, and E within 24 hours; nevertheless, symptoms progressed to complete quadriplegia. On day 8, she began moving spontaneously,
Jeremy Sobel, Tracy Dill, Christina L. Kirkpatrick, Laurel Riek, Patrick Luedtke, Todd A. Damrow   +5 more
doaj   +1 more source

Characterization of the binding of botulinum type B 16S toxin to human intestinal epithelial cells [PDF]

, 2007
Botulinum neurotoxin produced by Clostridium botulinum type B is a complex of 12S and 16S toxins. 12S toxin consists of a neurotoxin and a nontoxic non-HA (NTNH). The 16S toxin consists of a neurotoxin, an NTNH, and a hemagglutinin (HA).
Arimitsu H, et al., Fujinaga Y, et al., Fujinaga Y, et al., Oguma K, et al., Schiavo G, et al., Uotsu N, et al.   +5 more
core   +1 more source